Preliminary Program subject to change
15C02 Protein Engineering: Therapeutics
OverviewThe ability to create proteins with desired properties is limited by our current understanding of the relationships between protein sequence, protein structure and protein function and by our current abilities to search sequence space in an efficient manner. This session seeks presentations on emerging topics and recent successes in both the understanding and engineering of protein form and function. Experimental and computational approaches that are of scientific, medical, and industrial significance are sought after. Possible areas of interest include, but are not limited to: computational design, directed evolution, protein mutations and modifications including non-natural amino acids, antibody or cytokine engineering, and protein medicinal chemistry.
Primary SponsorBioengineering (15c)

Chair

Jennifer A. Maynard
Assistant Professor
Chemical Engineering
University of Texas, Austin
1 University Station, MC 0400
Austin, TX 78712
Phone Number: (512) 471-9188
Fax Number: (512) 471-7060
Email: maynard@che.utexas.edu

CoChair

David W. Wood
Professor
Princeton University
A213 EQUAD
Princeton, NJ 08544
Phone Number: 609 258 5721
Fax Number: 609 258 0211
Email: dwood@princeton.edu
Welcoming Remarks
Engineering Interleukin-2 For The Inhibition Of Regulatory T Cells
David V. Liu, Chemical Engineering, Massachusetts Institute of Technology, 50 Ames St., E19-563, Cambridge, MA 02139 and K. Dane Wittrup, Chemical Engineering and Biological Engineering, Massachusetts Institute of Technology, E19-551, Cambridge, MA 02139
Cell-Surface Display Of Antibody Fragments Containing Non-Canonical Amino Acids
James A. Van Deventer, Division of Chemistry and Chemical Engineering, California Institute of Technology, MC 210-41, 1200 E. California Blvd., Pasadena, CA 91125, Tae Hyeon Yoo, Division of Chemistry and Chemical Engineering, California Institute of Technology, 1200 E. California Blvd., MC 210-41, Pasadena, CA 91125 and David A. Tirrell, Division of Chemistry and Chemical Engineering, California Institute of Technology, 1200 E. California Blvd., Pasadena, CA 91125
A Comparison Of Novel Antibodies Isolated By Two Different Anchored Periplasmic Expression (Apex) Systems
Thomas J. Van Blarcom, Chemical Engineering, University of Texas at Austin, Molecular Biology Building, 2500 Speedway Room 3.310, Austin, TX 78712 and George Georgiou, Chemical Engineering, University of Texas at Austin, 1 University Station C0400, Austin, TX 78712
Engineering Transcription Factors with Novel DNA-Bind Specificity
Tasha Desai, Chemical and Biomolecular Engineering, University of Illinois, 600 South Matthews Ave., 211 Roger Adams Laboratory, Box C-3, Urbana, IL 61801 and Christopher V. Rao, Department of Chemical Engineering, University of Illinois, 600 South Matthews Ave., 211 Roger Adams Laboratory, Box C-3, Urbana, IL 61801
Break
Turning Ribosome Display Outside In For Intracellular Protein Engineering
Lydia M. Contreras, Cornell University, Ithaca, NY 14853 and Matthew P. DeLisa, Cornell University, Ithaca, NY 14850
Directed Evolution of Structured Peptides
Karuppiah Chockalingam, Chemical Engineering, Columbia University, 500 W 120th Street, New York, NY 10027 and Scott Banta, Chemical Engineering, Columbia University, 500 W 120th St, New York, NY 10027
Engineering High-Affinity, Specific Peptide Ligands To Vascular Endothelial Growth Factor
Sophia A. Kenrick and Patrick Daugherty, Chemical Engineering, University of California, Santa Barabara, Engineering II, Room 3357, Santa Barbara, CA 93106-5080
Concluding Remarks

Food, Pharmaceutical & Bioengineering Division